Arcus Biosciences (RCUS) said Tuesday that it has priced an underwritten offering of 13.6 million shares at $11 per share, for total proceeds of $150 million.
The company said it is selling all of the shares in the offering, which is set to be completed on Wednesday.
Arcus said the proceeds from the offering will be used to fund ongoing research and development, as well as for other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.